Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. 

Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for fixation strength and offer surgeons a reason to reassess their joint repair approach, including:

• Market-leading strength in all-suture anchor fixation*^1-5 and ultra-low displacement**^1,6-10
• Consistent deployment^4,11,12
• Best-in-class soft tissue security with our suture lock mechanism**⁵ 
• Streamlined suture shuttling⁵
• Market-leading biomechanical performance,^{† 1-4,6,7} with the lowest displacement during cyclic loading^‡1,3,6,7

The Q-FIX KNOTLESS All-Sutures Anchor offers a versatile range of suture options that include both single-loaded MINITAPE^◊ Suture Tape - which has a low profile and coreless design to offer a lower and more evenly distributed level of pressure^13,14 or ULTRABRAID^◊ #2 Suture that is 20% stronger than its nearest competitor.^{‡‡, 15} 

'When I think of the Q-FIX family I think of reliability,” commented Dr. Robert Litchfield, Orthopedic Surgeon, Sports Medicine Ontario, Canada. “We know that when we put a Q-FIX Anchor in, that we can count on it - the deployment is always predictable and the pullouts are impressive. In my experience, these anchors just don't fail when we put load on them.' 

For more information about the Q-FIX KNOTLESS All-Suture Anchor for shoulder repair, please visit here.

For more information about the Q-FIX KNOTLESS All-Suture Anchor for hip repair, please visit here.

- ends –

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

Footnotes

*As compared to competitive devices in fixation/pull-out benchtop testing. 

**As compared to the competitive device in cyclic benchtop testing.   

†As compared to competitive all-suture anchors in cyclic and fixation/pull-out benchtop testing. 

‡As demonstrated in benchtop testing; compared to competitive devices.

‡‡ As compared to competitive devices.

References

1. Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975.  
2. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275.  
3. Smith+Nephew 2023. Internal Report. 10090792- Revision B.  
4. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B.  
5. Smith+Nephew 2024. Internal Report. 10144423 Rev B.  
6. ArthroCare 2019. Internal Report. Anchor. P/N 49193-02 Rev B.  
7. Barber FA, et al. Arthroscopy. 2017;33(6):1113-1121. 
8. Nagra NS, et al. Bone Joint Res. 2017;6(2):82-89.  
9. Ruder JA, et al. Arthroscopy. 2019;35(7):1954-1959 e1954.  
10. Smith+Nephew 2023. Internal Report. 10090792 Rev B.  
11. ArthroCare Corporation 2016. Internal Report: P/N 49190-01 Rev.B.  
12. Smith+Nephew 2020. Internal Report. 17-5010-11.  
13. Smith+Nephew 2016.Feasability, MINITAPE Knot Stack Evaluation and Knot Security.15005268. Rev A
14. Smith + Nephew 2013.ULTRATAPE Pressure Film Testing. 15001847. Rev A.
15. Smith+Nephew 2006.USP Knot Strength, ULTRABRAID (white). ITR-2928. Rev E.

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

Forward-looking StatementsThis document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.